FDA Approves Guardant360 CDx for AstraZeneca’s Breast Cancer Drug, Shifting Treatment Paradigm
Event summary
- FDA approved Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in advanced breast cancer.
- Approval based on SERENA-6 trial data showing 56% reduction in progression or death risk with early ESR1 mutation detection.
- First FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer.
- Guardant360 CDx marks the 29th CDx indication across multiple tumor types globally.
The big picture
This approval validates a paradigm shift from reactive to proactive cancer management, leveraging liquid biopsies for earlier intervention. The collaboration with AstraZeneca positions Guardant at the forefront of precision oncology, with potential applications across multiple tumor types. The approval also underscores the growing clinical utility of Guardant360 CDx, now covering 29 indications and supporting better patient outcomes in advanced breast cancer.
What we're watching
- Adoption Pace
- How quickly oncologists will integrate ctDNA monitoring into standard practice for breast cancer management.
- Reimbursement Dynamics
- Whether Medicare and commercial payers will expand coverage for longitudinal liquid biopsy testing.
- Competitive Response
- How rivals like Foundation Medicine will react to Guardant’s expanded CDx portfolio in oncology.
Related topics